Studies in Treatment Phase & Follow-up
ABCSG 41 / OlympiA
A randomised, double-blind, parallel group, placebo-controlled multi-centre phase III study to assess the efficacy and safety of olaparib vs placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2-negative breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapyABCSG 42 / PALLAS
PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancerABCSG 43 / INSEMA
Comparison of axillary sentinel lymph node biopsy versus no axillary surgery in patients with stage I and II invasive breast cancer and breast-conserving surgery: a randomized prospective surgical trialABCSG 48 / POSITIVE
A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy (POSITIVE)ABCSG 49 / POLAR
A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancerABCSG 50 / BRCA-P
A randomized, double-blind, placebo-controlled, multi-center international phase III study to determine the preventive effect of Denosumab on breast cancer in women carrying a BRCA1 germline mutationABCSG 51 / AURORA
Aiming to understand the molecular aberrations in metastatic breast cancer: The AURORA programABCSG 53 / TAXIS / OPBC-03 / SAKK 23/16
Tailored axillary surgery (TAS) with or without axillary lymph node dissection (ALND) followed by radiotherapy in patients with clinically node-positive breast cancer. A multicenter randomized phase III trial.ABCSG 55N /AMBHER
Description of patients with HER2 positive breast cancer undergoing neoadjuvant treatment and development of a dynamic composite risk score to predict the risk of distant recurrence.ABCSG 56 / SASCIA
The ABCSG 56 / SASCIA is a GBG-sponsored, randomized, open-label, postneoadjuvant Phase III study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate, in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment.
ABCSG 60 / CAMBRIA-1
A phase III, open-label, randomized study to assess the efficacy and safety of extended therapy with Camizestrant versus standard endocrine therapy in patients with ER+/HER2- early breast cancer and an intermediate or high risk of recurrence who have completed at least 2 years of standard adjuvant endocrine-based therapy without disease recurrenceABCSG 62 / CAMBRIA-2
A phase III, open-label, randomized study to assess the efficacy and safety of Camizestrant (AZD9833, a next generation, oral selective estrogen receptor degrader) versus standard endocrine therapy (aromatase inhibitor or Tamoxifen) as adjuvant treatment for patients with ER-positive/HER2- negative early breast cancer and an intermediate-high or high risk of recurrence who have completed definitive locoregional treatment and have no evidence of disease.ABCSG 63 / ERIKA
An open-label, two-arm, randomized, phase II study of elacestrant plus ribociclib vs. AI (plus GnRH agonist in pre-/perimenopausal women and men) plus ribociclib as neoadjuvant therapy for endocrine-responsive HER2-negative early breast cancerABCSG C08 / EXERCISE
A randomized, phase III trial of endurance exercise following adjuvant chemotherapy for colorectal cancerShare on